Our mission is to provide novel drugs and treatments for respiratory viral infections
About us
Our novel treatments of microbial infections
Our optimized cationic peptidomimetic is the result of world-class research in the field of lytic peptides.
The lead compound LTX-109 is engineered based on an antimicrobial sequence in a naturally occurring peptide and does not seem to trigger development of resistance, ensuring a sustainable way of fighting off infections.
Effective first-line treatments against respiratory viral infections are still pose a huge unmet need. Pharma Holdings has developed a highly effective nasal spray to treat these infections. Our primary indication is Influenza in immunocompromised patients, with other indications to follow.
A broad spectrum and rapid mode of action
LTX-109 has a proven broad-spectrum antimicrobial effect against a variety of bacteria, both gram positive and gram negative, including multi-resistant bacteria. The effect is also proven in vitro and in vivo against a panel of respiratory viruses. It exerts its virucidal effect by disrupting the integrity of viral envelopes, inducing lysis and immediate inactivation of the virus.
"We have shown that LTX-109 is very effective at eliminating bacterial biofilms formed by Pseudomonas aeruginosa, in this case killing it at only four times the concentration needed to kill planktonic, non-biofilm bacteria. This level of efficacy is quite unheard of with most other antibiotics."
– Prof. John Sigurd Svendsen
Our vision is to contribute in the constant battle against global infections in an eco- friendly way by developing new potent drugs based on the nature’s on defense mechanism.